SCHEMBL6716797

SCHEMBL6716797

CN(C(=O)C(c1ccccc1)N(C(=O)O)C(C)(C)C)c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
TACR1 P25103 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
LMNA P02545 1/20 0.38
MAPK13 O15264 1/20 0.38
MAPK12 P53778 1/20 0.38
MAPK11 Q15759 1/20 0.38
MAPK14 Q16539 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ATM Q13315 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
GPBAR1 Q8TDU6 1/20 0.37
PGR P06401 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28637927 0.78 BRD4 (0.41) LMNASLC6A4MEN1KMT2APOLB
SCHEMBL18222299 0.77 PKM (0.41) SLC6A4MEN1KMT2ARAB9A
SCHEMBL18222289 0.77 PKM (0.41) SLC6A4MEN1KMT2ARAB9A
SCHEMBL6713979 0.76 ALDH1A1 (0.53) ALDH1A1GAAATMMEN1KMT2A
SCHEMBL17075965 0.75 ATM (0.40) ALDH1A1GAATACR1L3MBTL1KDM4E
SCHEMBL17075966 0.75 ATM (0.40) ALDH1A1GAATACR1L3MBTL1KDM4E
SCHEMBL6716828 0.74 SIGMAR1 (0.46) ALDH1A1KDM4EATMSLC6A2SLC6A4
SCHEMBL17076138 0.74 ATM (0.40) ALDH1A1GAAL3MBTL1LMNAKDM4E
SCHEMBL17076139 0.74 ATM (0.40) ALDH1A1GAAL3MBTL1LMNAKDM4E
SCHEMBL6726593 0.71 HDAC1 (0.44) HDAC1ALDH1A1GAAL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 HDAC1 3375/4885ALDH1A1 572/4885GAA 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.